Gabriela Marton sets out some of the EU-associated regulatory challenges life sciences companies will need to navigate if they want to take advantage of the rise of biosimilars.
Biological medicines represent a major advance in the treatment of serious pathological conditions such as cancer, neurodegenerative and autoimmune diseases. Biosimilars, their cost-effective alternatives, enable improved patient access to modern therapies. As these therapeutics become trusted and more widely used by clinicians, we can expect a larger number of biosimilars coming onto the market as the patents and market exclusivity linked to innovator products expire. By 2019, more than 14 innovative biological products lost their Orphan Drug Designation (ODD) market exclusivity and by 2029 this will increase by a further 34 products. By 2023, patents will expire for most formulations, creating a fruitful period to develop important biosimilars.
While biological drugs are the originators of new treatments, such products are costly to develop and procure. A newly-developed molecule can take 10 to 15 years in the development phase and incur over one billion euros or dollars in R&D costs. Once that formula’s patent and market exclusivity expires, competing manufacturers can bring a biosimilar to market at a fraction of the price, enabling cheaper options for governments and potentially providing patients much wider and more affordable access to treatments. These products might take 30 to 50 percent less time to develop and cost up to 70 percent less than their biologic originals – savings that can be passed on to healthcare providers and patients. To date, biosimilars are thought to have saved the EU up to $44 billion in healthcare costs.1
Biosimilar treatments offer similar benefits for the healthcare system as generic drugs, although they cannot be compared. Generics are small-molecule formulations identical to the innovative product, while a biosimilar can only aim to be highly similar to the innovative product. However, both generic and biosimilar products are expected to have the same clinical effect as their respective innovative products.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
As biologics are important in the treatment of oncological, rheumatological, endocrinological and other rare diseases, increasing numbers of manufacturers are moving from small-molecule developments to the more complex process of developing larger molecules.
Identifying the opportunity
As biosimilars are not biologically identical to their reference products, when companies are undergoing regulatory assessments they can re-use information developed by the original innovator company. This can expedite the development of the biosimilar; an enhanced comparative quality study is recommended, rather than extensive clinical and non-clinical studies to support product registration.
For ODDs, biosimilars offer speed to market with cost-effective medicines, providing patients affordable access to the treatments they need. This is not only due to the lower cost of development of biosimilars versus biological innovator originals, but also increased market competition and the emerging regional or country policies designed to attract more biosimilar treatment alternatives. Most biosimilar products are introduced into markets through tenders. We have seen 85 percent discounts achieved in Norway and 45 percent in France, following local negotiations. The increased competition also forces originator biologic manufacturers and sellers to bring their own pricing down on their innovative products, further adding to the affordability of important treatments.
Our assessments of the available market information reveal that in 2019, an average ratio of 3.5 market concentration for biosimilars per originator was achieved in Europe. The price reduction of the originator after the introduction of biosimilars reached more than 60 percent in Portugal for erythropoietin (EPO), a hormone produced by the kidneys to stimulate production and maintenance of crucial red blood cells. The price per treatment per day came down by an average of 30 percent.
Building consensus and trust around alternative large-molecule treatments
Interest in biosimilars is growing, as understanding grows around this alternative route to medicines access and trust builds. Initially, there was apprehension about the safety of any interchangeability in the treatment between biosimilar and originator and vice-versa, or between two biosimilars. This was likely because biosimilars are not exact equivalents of reference drugs, they may not come in the same pharmaceutical dosage as the originator and that testing can reveal insignificant clinical differences. Yet, as multiple studies have been performed to demonstrate the low risks of interchangeability and as authorities’ interest in supporting such studies has increased to be able to indicate where impeachability is recommended, these concerns have decreased in intensity.
Biosimilars… enable improved patient access to modern therapies”
Agreement among the various authorities about how to handle biosimilars will also help. Today, more than 70 biosimilars are registered in the EU and others are under evaluation. This is due to efforts by the European Medicines Agency (EMA) to continuously improve guidelines and provide the appropriate support to bring these products to market. Similar efforts have been seen across each national drug authority around Europe and the Heads of Medicines Agencies (CMDh), to provide access to biosimilars.
There is a way to go, however. Currently, there is no harmonised approach towards interchangeability in Europe. Rather, each member state’s national medicine authority can make decisions on a case-by-case basis.
The emergence of best-practice policies
More encouragingly, most European countries have now succeeded in achieving widespread acceptance of biosimilars by all parties: payers, providers and patients. It is important that all parties understand the benefits of having such medicines available on the market.
In the Nordic countries, biosimilars are being introduced very rapidly, which has led to the impressive price competition mentioned above and wide-scale patient access to important treatments.
Other governments have introduced initiatives to increase biosimilar strength in the market. In France, where patient associations have an influence in policy creation, there is a plan to achieve 80 percent penetration during the current year. In France, Belgium, Germany and Sweden, government policy has seen incentives introduced for manufacturers, hospitals and patients.
Further examples of the diverse policies across Europe include Germany’s programme, which offers full reimbursement from day one, at a set price, ensuring immediate access to biosimilars. Here, local clinical guidelines are being developed to encourage biosimilar use as the first choice, as appropriate.
Meanwhile Sweden is organising multiple tenders per region to encourage multiple manufacturers to operate in the market, driving competition and maximising patient access to affordable treatments.
Navigating the complexity
The picture that is building is a potentially complex one; with so many factors differing from one market to the next, there are a lot of pieces to fit together once biosimilarity is demonstrated and products are authorised.
…national governments will need to invest in a proper infrastructure to support the biosimilar opportunity”
Companies may need some help navigating the differences, as the balance achieved by good policies can be easily destabilised by measures ranging from exclusive tenders (which can negatively impact biosimilar sustainability and lead to supply shortages), to fixed reimbursements pricing (which can destabilise competitive markets and discourage manufacturers’ participation). There are also many countries that do not yet have a policy for incentives or have not yet fully implemented more recent policies.
In some countries, policies are ensuring that market volumes are guaranteed, whereas in others there is no such guarantee so after price readjustment, market volumes are lost.
The education imperative
Other challenges are linked to education. Education around biosimilars is sorely needed, not only for healthcare professionals but also for patients, decision-makers and perhaps also the media – not just about the differences and relative benefits between biologics and biosimilars, but also how such products come into use and how they are administered.
This education is vital for building trust and supporting interchangeability in treatment, where applicable. Without this confidence in substituting original treatments with new biosimilars, healthcare professionals will continue to recommend the reference product, which will stifle competition and lead to price increases over time, a phenomenon also seen in generics.
Responding to market forces
For life sciences companies, biosimilars present an exciting opportunity to bring important treatments to market more affordably and in higher volumes, putting the needs of patients first.
As more biological products lose their exclusivity, there is likely to be a race to bring biosimilars to market and companies that hold back could lose significant ground.
Competition will also be stimulated by emerging biopharma companies engaging in dynamic partnerships, a phenomenon that is already in evidence. In January 2020, Mundipharma announced a partnership with Samsung Bioepis to commercialise the latter’s first-wave biosimilar candidates in Taiwan and Hong Kong. The partnership applies to Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology and includes SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab) and SB8 (bevacizumab) and this is only one of numerous examples.
For medicine manufacturers, the ability to develop and roll out the right products at the right price and in sufficient volumes is paramount to keep pace with market demand and fulfil patients’ needs. Europe is a great place to get this right, as the EU authorities have the most advanced understanding and emerging policies. The US Food and Drug Administration (FDA) is catching up quickly too, presenting a huge expansion opportunity. The US market also has interest in creating cohesive guidelines and legislation around biosimilars interchangeability, something that is still lacking at the EMA. Japan is also taking a proactive interest in the field. The hope is that respective national and regional regulators will increasingly share best practice rather than reinvent the wheel for their own market.
For their part, national governments will need to invest in a proper infrastructure to support the biosimilar opportunity, with attractive policies and incentives for biosimilars manufacturers to invest in development and commercialisation of these products, to ensure competitive and sustainable supply and affordable pricing. This all needs to be supported by an education drive, so that all of the parties involved understand the important role played by biosimilars and the broader potential for transforming global patient access to the latest treatments.
About the author
Gabriela Marton is Regulatory Affairs Director and Quality Director at Arriello, where she leads the regulatory affairs functions, developing robust and efficient market access and post-marketing strategies to support pharmaceutical companies’ business needs. She has over 14 years’ experience in regulatory affairs and compliance within the pharmaceutical and food supplements sectors. Previously, she was an independent regulatory consultant and has held several positions in regulatory affairs and compliance in various pharmaceutical companies, one of which is GlaxoSmithKline (GSK) where she started her regulatory career.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.